The roles of ghrelin, a peptide hormone that has a role in regulating food intake and energy homeostasis, in the cardiovascular system have not yet been unambiguously established. We evaluated the association between plasma ghrelin concentrations and À501A4C single-nucleotide polymorphism (SNP) in the ghrelin gene 5 0 flanking area and echocardiographic measurements in 1037 middle-aged subjects. Left ventricular mass index (LVMI) was calculated according to Devereux's method. The ambulatory blood pressure (BP) was recorded using the fully automatic SpaceLabs 90207 oscillometric unit. Results suggested that plasma ghrelin was not related to mean ambulatory BP values. However, the highest plasma ghrelin tertile was associated with increased intraventricular septum (P ¼ 0.043) and posterior ventricular wall (P ¼ 0.002) thicknesses as well as left ventricular mass (P ¼ 0.05). After adjustment for age, sex, body mass index and systolic BP, the association persisted between ghrelin tertiles and intraventricular septum (P ¼ 0.05) and posterior ventricular wall (P ¼ 0.001) thicknesses. The SNP À501A4C polymorphism was associated with LVMI after adjustments for age, sex and systolic BP. In conclusion, ghrelin and its promoter variant are associated with cardiac hypertrophy indexes independent of BP. Positive correlation between ghrelin levels and increased wall thickness parameters may reflect compensatory up-regulation of ghrelin concentrations or direct effects of ghrelin on myocardium. The effects of the SNP seem not to be mediated through its effects on ghrelin plasma levels.
Introduction
Ghrelin is a blood-borne orexigenic signal from gut to brain, 1 with diverse hormonal and metabolic activities.
2 Ghrelin 3 and its receptor 4 are synthesized and secreted also by human and mouse cardiomyocytes. Ghrelin may protect cardiomyocytes from apoptosis, probably by paracrine/autocrine actions. 4 Ghrelin might also have other beneficial effects on heart function and hemodynamics. It has been shown that acylated as well as des-acyl ghrelin protect cardiomyocytes from isoprenalin-induced injury in rodents, although the cardioprotective effects of des-acyl ghrelin were weaker than those of acylated ghrelin. 5 Furthermore, ghrelin might decrease the activity of the sympathetic nervous system in rabbits. 6 Intravenous injection of ghrelin not only decreased arterial pressure, but also increased cardiac output in healthy humans. 3 There are also promising preliminary human studies addressing that ghrelin might improve heart function in patients with chronic heart failure. 7 Supraphysiological levels of ghrelin stimulated left ventricular (LV) function in healthy young normalweight men. 8 Ghrelin might have a role in patients with end-stage heart failure and cardiac cachexia, by improving cardiac function and increasing appetite. 9 In addition, serum ghrelin has been associated with right ventricular cardiovascular indexes. 10 Recently, acylated ghrelin was reported to be positively associated with systolic blood pressure (BP) and left ventricular mass indices (LVMIs) in patients with the metabolic syndrome, even after correction for body mass index (BMI). 11 Common variants in the ghrelin receptor region were also shown to be associated with parameters of LV mass and geometry independent of BP and body mass in the general population and, thus, may be involved in the pathogenesis of left ventricular hypertrophy (LVH). 12 The purpose of our study was to further clarify the association between plasma ghrelin levels and genetic variations suggested to determine ghrelin expression and plasma levels with echocardiographic measurements, such as LVMI, in a study population consisting of 1037 middle-aged subjects of the Oulu Project Elucidating Risk of Atherosclerosis project. The relationship between the circadian profile of BP, dipping pattern and plasma ghrelin levels, not studied earlier, was also analyzed.
Methods

Subjects
This study is a part of the Oulu Project Elucidating Risk of Atherosclerosis project, which is a population-based, epidemiological study designed to address the risk factors and disease end points of atherosclerotic cardiovascular diseases. The study population and selection criteria have been previously described in detail. 13 The study population consists of a hypertensive cohort (300 men and 300 women) and a control cohort (300 men and 300 women) living in the city of Oulu and who were 40-59 years old at the time of recruitment. The hypertensive cohort was randomly selected by age stratification (15 men and 15 women per year) from the Social Insurance Institute register for reimbursement of antihypertensive medication. According to the register, they were entitled to a special refund (higher reimbursement class) of antihypertensive medication. For each hypertensive subject, an ageand sex-matched control was randomly selected from the national health register (including all inhabitants) excluding any subjects with the right to reimbursement for hypertension medication. The study was approved by the Ethical Committee of the University of Oulu, and all the subjects volunteered to participate. The study complies with the Declaration of Helsinki.
Clinical measurements
At the visit, anthropometric measurements (weight, height, waist and hip) and BP measurements were carried out. BMI was calculated as weight (kg) divided by height squared (m 2 ). Body surface area was determined by the Dubois equation. 14 All BP measurements were recorded with an automatic oscillometric BP recorder (Dinamap, Critikon Ltd, Ascot, UK) and the procedure of measurement was made according to the recommendations of the American Society of Hypertension. The resting BP was measured as a total of three times at 1 min intervals on the right arm after the subject had been seated for a minimum of 5 min. The BP value used in the analyses is the mean value of the second and the third BP measurement.
Ambulatory BP was recorded using the fully automatic SpaceLabs 90207 oscillometric unit (SpaceLabs Inc., Redmond, WA, USA), which was set to take a measurement every 15 min from 0400 hours till midnight and every 20 min from midnight till 0400 hours. 15 A reduction in systolic BP from daytime to nighttime o10% was considered to represent a non-dipping pattern.
Laboratory analyses were acquired after an overnight fast. Plasma was separated by centrifugation and stored at À20 1C. Fasting ghrelin concentrations were measured from plasma samples stored at À20 1C using a commercial RIA kit (PhoenixPharmaceuticals Inc., Belmont, CA, USA). 16 Ghrelin promoter single-nucleotide polymorphism (SNP) À501A4C variant was analyzed by the restriction fragment length polymorphism technique as described earlier. 17 Echocardiographic methods A Hewlett-Packard ultrasound color system Sonos 500 (Hewlett-Packard Company, Hingham, MA, USA) was used for the echocardiographic examinations. All procedures were performed by one experienced cardiologist (Markku Ikäheimo), who was blinded to the other data and grouping of the study subjects. M-mode measurements were obtained under 2D guidance according to the recommendations of the American Society of Echocardiography. 18 The LVM was calculated using the formula of Devereux et al. 19 and the LVMI by dividing the difference between the LVM values by body surface area. Fractional shortening was calculated by dividing the difference between the LV internal dimensions in diastole and systole by the diastolic dimension and then multiplying that value by 100. Transmitral flow velocities were measured by pulsed Doppler at the tips of the mitral leaflets from an apical transducer position, and the ratio of maximum early and late diastolic filling was calculated.
Statistical methods
The data were analyzed with SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). The data are presented as mean (95% confidence intervals) unless otherwise stated. The adjustment for confounding factors was performed using the analysis of covariance in the general linear model. LVMI was not adjusted for BMI since body weight is already included in the Deveraux's formula. P-values o0.05 were considered statistically significant. When analyzing frequency differences, a w 2 test was used. Logarithmic transformation was performed for some phenotypes because of skewness (left ventricular mass and LVMI).
Results
Plasma ghrelin levels and BP variation Plasma ghrelin was associated with BMI (P ¼ 0.002). Although plasma ghrelin was associated within office systolic and diastolic BPs before adjustments, the adjustment for age, sex and BMI deleted these associations (Table 1) . Considering ambulatory BP measurements, no associations were observed between ghrelin and day-or nighttime BP or dipping status. Leisure time physical activity level did not differ between ghrelin tertiles. Table 2 shows the use of selected medications among ghrelin tertiles and no differences were observed.
Plasma ghrelin levels and echocardiographic measurements
In order to analyze the association between plasma ghrelin levels and the echocardiographic measurements, the cohort was subdivided into ghrelin tertiles. The cardiac ultrasound indexes in relation to ghrelin tertiles in all subjects before and after adjustments are presented in Table 3 . The results demonstrate that the highest plasma ghrelin tertile was associated with increased intraventricular septum (P ¼ 0.043), posterior ventricular wall (P ¼ 0.002) and LV mass (P ¼ 0.05). After adjustment for age, sex, BMI and systolic BP, the association persisted between ghrelin tertiles and intraventricular septum (P ¼ 0.05) and posterior ventricular wall (P ¼ 0.001).
When the level of IGF and hematocrit, the latter as an index of blood volume, was included in the multivariate analysis, all the above significant associations remained the same (data not shown).
The above associations showed similar trends both in the hypertensive and control populations (data not shown). When subjects were divided into those with (n ¼ 327) and without (n ¼ 613) metabolic syndrome, the association between ghrelin levels and posterior ventricular wall (but not other echocardiographic parameters) was significant in the subjects without metabolic syndrome (P ¼ 0.012), but was only a trend among those with metabolic syndrome (P ¼ 0.074).
SNP À501A4C and echocardiographic measurements No significant differences in the total ghrelin plasma concentrations or BP between the SNP À501A4C genotypes were observed. However, the SNP À501A4C polymorphism was associated with LVMI after adjustment for age, sex and systolic BP (Po0.05). LVMI was the lowest in the subjects who were C allele homozygotes compared with those who were A allele homozygotes (Table 4 ; Figure 1 ). The SNP À501A4C polymorphism showed also association with the LV internal diameter with subjects with A/A genotype having the highest and C/C genotype the lowest value (P ¼ 0.017). Ghrelin levels and left ventricular hypertrophy O Ukkola et al
Discussion
The major finding of the present study was that high plasma ghrelin levels were associated with the values of some echocardiographic parameters, such as increased intraventricular septum and posterior ventricular wall. Furthermore, ghrelin promoter variant was associated with LVMI and LV internal diameter. Our findings remained statistically significant after adjustments for the major commonly recognized risk factors for LVMI, such as age, sex, BMI and systolic BP. As far as we are aware, this is the first study reporting an association between plasma ghrelin and its genetic variant with echocardiographic parameters estimated with such a large sample size. Plasma ghrelin seems not to be related to mean 24-h BP values either during day-or nighttime.
In patients with chronic heart failure, 3-week administration of ghrelin has been shown to increase LV ejection fraction in association with an increase in LV mass. 7 The mechanisms involved may be GH dependent or direct effects of ghrelin on myocardium. 7 In our study, the association between plasma ghrelin and cardiac indexes was independent of arterial hypertension and may be linked to the hyperactivity of the GH/IGF-I axis. Ghrelin stimulates strongly GH secretion in humans. 20 GH is known to increase cardiac mass. 21 However, ghrelin seems to improve endothelial dysfunction and increase endothelial nitric oxide synthase expression in GH-deficient rats, 22 implicating that the cardiovascular effects of ghrelin are at least partially, if not totally, GH independent. Also, in the current study, the associations between echocardiographic parameters and ghrelin were IGF-1 independent. Positive correlation between ghrelin levels and increased intraventricular septum and posterior ventricular wall may reflect compensatory up-regulation of ghrelin concentrations. Acylated Table 3 The echocardiographic measurements in the ghrelin tertiles in all of the subjects Ghrelin tertiles Table 4 The echocardiographic measurements by a 501A4C SNP genotype Ghrelin levels and left ventricular hypertrophy O Ukkola et al but not unacylated ghrelin was reported to be positively associated with high BP and increased LVM in patients with the MetS in a recent report. 11 It was hypothesized that elevated acylated ghrelin concentrations may represent a compensatory mechanism to overcome the development of hypertension and LVH in obesity. In the present study, the associations between ghrelin and echocardiographic parameters were somewhat stronger among those without metabolic syndrome and we used a commercial RIA kit recognizing both acylated and desacylated ghrelin. The measurement of total ghrelin is reasoned since the measurement of acylated ghrelin immunoreactivity from plasma samples stored in freezer might have given erroneous low concentrations. In addition, non-acylated form of ghrelin has non-endocrine functions and the stimulatory effects of ghrelin on anabolic insulin signaling has been previously reported in cardiomyocytes. 23 We have reported earlier negative correlation between both systolic and diastolic BP measured in office and fasting plasma ghrelin concentrations in the same population. 16 The high BMI levels of the subjects with low ghrelin seems to explain the association between low ghrelin concentrations and elevated BP. Ambulatory BP did not show any relation to plasma ghrelin levels supporting the notion that ghrelin is not the main regulator of BP in humans. In the current study, the positive correlation between plasma ghrelin and cardiac hypertrophy indexes were independent of BP and BMI. Interestingly, our earlier results suggested plasma ghrelin concentrations to be positively associated with carotid artery atherosclerosis in males. 24 A 501A4C SNP in the 5 0 flanking area of the ghrelin gene was associated with LVMI. We have earlier reported that the variants in the putative regulatory areas of the ghrelin gene are not having an important role in the regulation of ghrelin concentrations. 17 The polymorphism was not associated with BP values in contrast with an earlier study, where the effect of 501A4C SNP on BP regulation was found to be significantly modulated by other ghrelin SNPs with its C allele conferring either an increased risk or a decreased risk of hypertension according to the two different haplotypes on which it can be found. 25 However, the results of the present study suggest that the promoter variant might be associated with LVH; 501A4C SNP polymorphism is located in a non-coding region and do not cause a change in the amino-acid sequence of the ghrelin molecule. Interestingly, differences in the regulation of the ghrelin gene according to promoter sequence variants have been observed. 26 Either a functional analysis, such as reporter gene assay, or a physiological test, such as daily variation of plasma concentration, should be done with this and earlier observed polymorphisms in the future. Interestingly, plasma ghrelin level seemed to be associated more with wall thickness parameters, while the SNP with LVMI and internal diameter. This supports the notion that the effects of the SNP are not mediated through its effects on ghrelin plasma levels and mechanisms for its effects remain unknown. It can be speculated that the SNP, or another variant in linkage disequilibrium, may affect levels of unknown neuroendocrine factors contributing to the development of cardiac hypertrophy. It is also possible that these associations are caused by chance or confounding factors.
In conclusion, ghrelin may have hypertrophic effects to some parts of the myocardium. Plasma ghrelin level did not associate with ambulatory BP or dipping pattern. Ghrelin gene promoter 501A4C SNP polymorphism is related to LVMI. Experimental and prospective studies are warranted to elucidate the role of ghrelin in LVH.
